It depends on what peptide and the person
Their PAs go through the patient's existing Part D plan, as they always have
(Marinalg 2015 Marinalg International
6 In the UK, patients typically qualify for GLP-1 agonists if they have a BMI 30 kg/m 2 (classed as obesity) or a BMI 27 kg/m 2 (classed as overweight) if you also have weight-related issue such as high cholesterol, pre-diabetes, increased BP etc
This high price point limits accessibility for many patients, particularly in lower-income segments of the GCC population
Because of these effects, GLP-1 medications are commonly used for: Type 2 diabetes management Medical weight management Appetite control Supporting healthier metabolic function For suitable patients, these medications may help reduce weight gradually and improve health markers when used under medical supervision